Quantitative dot blot method for measuring EGFR protein levels in patients with colorectal cancer Authors: Ze Li, Na Li, Quanyong Li, Wenlei Xu, Guohua Yu, Wenguo Jiang Published: 2026 ABSTRACT PurposeThe expression levels of the epidermal growth factor receptor (EGFR) may be associated with the efficacy of cetuximab (CTX); however, conventional immunohistochemical assays lack quantitative accuracy and standardization, thereby making it hard to achieve absolute quantification of protein expression and cross-platform comparisons. To establish an objective quantitative standard for EGFR protein expression levels, we employed quantitative dot blotting (QDB) to analyze tumor samples from patients with RAS/BRAF wild-type colorectal cancer (CRC).Materials and methodsWe collected 89 formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens from patients with CRC stored at Yuhuangding Hospital in Yantai for QDB testing. Of these, 42 served as untreated controls, and 47 patients received CTX treatment.ResultsEGFR protein levels in all patients with CRC ranged from 0.05 to 3.85 nmol/g (n = 89). Using the predefined cohort-wide cutoff of 0.23 nmol/g, a chi-square test performed using the Statistical Package for the Social Sciences software revealed that patients with low EGFR expression had longer overall survival, regardless of CTX treatment.ConclusionsThis study established a QDB-based assay capable of quantitatively and objectively measuring EGFR protein levels in CRC specimens. This assay helps establish the value of EGFR protein as a predictive biomarker and is expected to assist in the retrospective and prospective evaluation of anti-EGFR therapies in clinical trials. Introduction In 2020, colorectal cancer (CRC) accounted for 9.4% of cancer-related mortality, ranking second after lung cancer [1]. By 2040, the global burden of CRC is projected to reach 3.2 million new cases [2]. The rising incidence of CRC remains a public health challenge, despite therapeutic advances [3]. Increasing evidence suggests that complex regulatory networks govern CRC progression. Key oncogenic drivers, including KIF20A, have been implicated in promoting tumor growth and metabolic reprogramming through the c-Myc/HIF-1α signaling axis [4]. Furthermore, the spectrum of non-synonymous and deleterious variants identified through exome sequencing offers key insights into genetic predisposition [5]. Concurrently, non-coding RNAs play pivotal roles. For instance, circular RNA hsa_circ_0005939 upregulates UHRF1BP1L by sponging miR-4693-3p, thereby promoting CRC progression [6]. Similarly, LINC01836 functions as a competitive endogenous RNA, regulating SLC17A9 by sponging miR-1226-3p [7]. The exact role of EGFR protein quantification in guiding targeted therapy remains unclear, despite these advances. Clinical management of CRC encompasses surgical resection, systemic chemotherapy, and targeted therapy. However, the lack of effective early screening strategies results in a persistently low rate of early-stage diagnosis. Consequently, at initial presentation, ∼80% of patients are diagnosed with locally advanced or metastatic disease. At this stage, systemic therapy becomes the mainstay of management, aimed at prolonging survival [8]. Although conventional chemoradiotherapy can extend survival, the median overall survival (OS) remains under 24 months, with systemic toxicities often leading to reduced tolerability and treatment discontinuation [9]. However, similar to conventional cytotoxic agents, targeted therapies inevitably develop significant drug resistance, leading to treatment failure [10]. Consequently, drug resistance is a key obstacle to improvements in CRC treatment [11]. Cetuximab (CTX) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and represents a key milestone in developing targeted therapy for CRC. It is currently among the most widely used targeted agents for CRC in clinical practice [12]. CTX binds with high affinity to the extracellular ligand-binding domain of EGFR and inhibits the binding of endogenous ligands. Consequently, EGFR activation and phosphorylation, as well as downstream signaling cascades, are attenuated, thereby suppressing tumor cell proliferation and inducing apoptosis [13,14]. Emerging findings suggest that combining CTX with chemotherapy provides clinical benefit in patients with RAS/BRAF wild-type CRC [15]. However, despite initial therapeutic efficacy, the median duration of response is limited to 12–18 months, owing to the development of acquired resistance, leading to treatment failure [11,16]. Although resistance is largely attributed to EGFR bypass signaling [17], we hypothesized that its severity may correlate with EGFR expression levels. Therefore, precise and absolute quantification of EGFR expression is critically important. Since its introduction nearly four decades ago, Western blotting has remained the predominant immunoblotting technique in basic research [[18], [19], [20], [21], [22]]. However, this technique is associated with inherent limitations, including labor-intensive workflows, limited throughput, subjective data interpretation, and substantial sample consumption, which preclude its application in high-throughput settings. Quantitative dot blotting (QDB) offers a simplified alternative to Western blotting [23]. It converts conventional immunoblotting into a robust quantitative assay, within a defined linear range [24]. The QDB method has been used to quantify human epidermal growth factor receptor 2 (HER2) and Ki67 in breast cancer, as well as EGFR in gastric cancer, highlighting its translational potential [[24], [25], [26], [27]]. In these assays, subjective visual scoring is replaced with a microplate reader to quantify the signal. Each sample is assayed in triplicate, using an internal control with known EGFR concentrations to ensure reproducibility. Consequently, the QDB assay is streamlined, objective, and reproducible, enabling absolute protein quantification. This study presents a QDB-based assay for the absolute quantification of EGFR protein in CRC tissues. This assay provides a robust establishment of EGFR as a predictive biomarker and enables patient stratification based on EGFR expression levels for CTX therapy. Furthermore, it enables prognostic assessment and guides clinical decision-making. Materials and methods Human subjects A total of 89 formalin-fixed, paraffin-embedded (FFPE) CRC resection specimens were collected retrospectively from Yantai Yuhuangding Hospital. All specimens were derived from patients with RAS/BRAF wild-type tumors; 42 patients had not received CTX therapy, while 47 had. All experimental procedures were conducted in compliance with relevant regulations and institutional guidelines and received approval from the Ethics Committee of Binzhou Medical University (Approval No. DYPD2023-290). Patient confidentiality was maintained, and informed consent was obtained for using human specimens. General reagents Chemical reagents were received from Sinopharm Chemical Reagent Co., Ltd., Beijing, China. Recombinant human EGFR protein (Catalog No. 10001-H20B2) was obtained from Sino Biological Inc., Beijing, China. The rabbit anti-EGFR monoclonal antibody (clone EP22) was received from ZSGB-BIO, Beijing, China. QDB plates were supplied by Yantai Zestern Biotechnology Co., Ltd., Yantai, China. Preparation of FFPE tissue Two FFPE tissue slices of 5 μm each (2 × 5 μm) from each specimen were placed into 1.5 mL Eppendorf tubes. Rehydration was conducted following dewaxing with xylene for 10 min. Centrifugation was performed at 12,000 × g for 3 min, after air-drying of the tissue particles. The supernatant was discarded, and 150 μL of lysis buffer (comprising 100 mM HEPES, 100 mM NaCl, 5 mM EDTA, 1 mM MgCl2, 10 mM Na2P2O7, 1% Triton X-100, and 10% glycerol) was added. Samples were incubated at 98 °C for 20 min, followed by rapid transfer to 80 °C for 2 h. Samples were centrifuged at 14,000 × g at 4 °C to harvest the supernatant. Cell protein extraction CT26, Caco-2, SW480, and HT-29 CRC cells were collected, resuspended in lysis buffer, and lysed using sonication for 30 s. Following centrifugation at 12,000 × g for 20 min, the supernatant was recovered, and protein concentration was determined. Western blotting Protein lysates were resolved by SDS-PAGE using an 8% polyacrylamide gel and transferred onto a PVDF membrane. The membrane was blocked for 1 h at room temperature with 5% non-fat dry milk. The membrane with the primary antibodies was incubated overnight at 4 °C. Primary antibodies (anti-EGFR, 1:1000; anti-β-actin, 1:2000) were diluted in TBST containing 5% BSA as the primary antibody dilution buffer. Following three washes with TBST, the membrane was incubated with HRP-conjugated secondary antibodies. Band intensity was quantified using ImageJ (National Institutes of Health, Bethesda, MD, USA). Signals with a signal-to-noise ratio (SNR) ≥ 5 were considered positive. SNR is defined as the ratio of band grayscale intensity to minimum background intensity. QDB analysis Quantitative analysis of EGFR in samples and standards was performed using QDB technology, according to previously described protocols [24,26]. Guided by the established linearity of the QDB assay (0–1 μg, R2 = 0.997) and the observation that signal saturation occurred beyond 1 μg (Fig. 2C), protein lysates were diluted to a working concentration of 0.4–0.6 μg/μL before loading onto the QDB plate. EGFR standard proteins, test samples, and controls were spotted sequentially onto the QDB plate at a volume of 2 μL per spot. The EGFR standard curve consisted of serial dilutions ranging from 0 to 150 pg/μL (0, 1.25, 2.5, 5, 10, 25, 75, and 150 pg/μL). Standard proteins, samples, and controls were loaded in triplicate. Following dispensing, the QDB plate was allowed to dry at room temperature for 4 h. The QDB plate was blocked in TBST containing 4% non-fat dry milk at room temperature on a shaker at 100 rpm for 1 h. The EGFR primary antibody was diluted 1:1000 in TBST containing 4% non-fat dry milk, and 100 μL was added to each well of a 96-well plate. The blocked QDB plate was incubated overnight at 4 °C on a shaker at 100 rpm with the protein side facing down onto the antibody solution. On the following day, QDB plates were removed and washed twice with TBST for 1 min each at 160 rpm. The donkey anti-rabbit secondary antibody was diluted 1:2500 in TBST containing 4% non-fat dry milk, and 100 μL was added to each well of a 96-well plate. The washed QDB plates were incubated with the secondary antibody solution for 4 h on a shaker at 100 rpm. QDB plates were rinsed twice with TBST for 1 min at 160 rpm, followed by five additional washes for 10 min each. The ECL chemiluminescent substrate was equilibrated to room temperature. Subsequently, 100 μL of ECL substrate was added to each well of a white 96-well plate. Subsequently, the QDB plate was placed into the white 96-well plate, allowed to react for 3 min, and the luminescence intensity was measured using a microplate reader. Statistical analysis Categorical variables, including EGFR expression levels (high versus low) and mortality status, were analyzed using the Chi-square (χ2) test. Assumptions of the test were verified before analysis, confirming that expected frequencies were > 5 in ≥ 80% of cells. Continuous variables, such as age, were analyzed using an independent-samples t-test. Statistical significance was set at P < 0.05. Post-hoc power analysis was performed using G*Power 3.1 (Heinrich Heine University, Düsseldorf, Germany) to assess the statistical power of our subgroup analyses. The analysis was based on the observed effect sizes, a significance level of 0.05, and the observed sample sizes of the subgroups. The primary EGFR expression cutoff value of 0.23 nmol/g was predefined based on ROC analysis for mortality outcomes in the full study cohort. To minimize overfitting to random noise from small subgroups, the optimal cutoff for EGFR expression was determined by ROC analysis across the entire study cohort, rather than by separate ROC analyses within individual treatment subgroups. Subgroup-specific ROC-based thresholds were not adopted in the primary analysis, because thresholds derived from limited-size subgroups are susceptible to chance-driven variation. This unified threshold was applied consistently for all subsequent stratification, including all subgroup analyses of CTX-treated and non-CTX patients. The QDB assay enables standardized analytical quantification of EGFR protein across samples, and application of a single cohort-wide prognostic cutoff further supports consistent interpretation across patient groups. This cohort-wide threshold preserves the standardization merit of the QDB quantitative detection platform and permits unbiased, fair comparison of EGFR predictive performance among different treatment subgroups. Results Validation of Anti-EGFR antibody specificity The specificity and applicability of the anti-EGFR antibody were evaluated by analyzing whole-cell lysates from CT26, Caco-2, SW480, and HT-29 cells through Western blotting, as QDB assays require high antibody specificity. Western blotting results demonstrated that the antibody exhibited high specificity (Fig. 1A). Densitometric analysis revealed that HT-29 cells exhibited the highest EGFR expression (Fig. 1B). Consequently, for the dose-response analysis, HT-29 cell lysates were serially diluted across a concentration range of 0.01–9 μg. In contrast, Western blotting failed to detect signals at concentrations below 1 μg (Fig. 1C).Fig. 1Validation of Anti-EGFR Antibody Specificity. (A) Western blotting analysis of EGFR expression across various CRC cell lines. (B) Comparative analysis of EGFR expression levels among the cell lines. (C) Sensitivity assessment of Western blotting for EGFR detection in HT-29 cells.Fig. 2Feasibility and Validation of the QDB Assay. (A) Quantitative analysis of EGFR protein using QDB. (B) Calibration curve spanning 0.01 to 9 μg. (C) Linear dynamic range of the QDB assay. Validation of Anti-EGFR Antibody Specificity. (A) Western blotting analysis of EGFR expression across various CRC cell lines. (B) Comparative analysis of EGFR expression levels among the cell lines. (C) Sensitivity assessment of Western blotting for EGFR detection in HT-29 cells. Feasibility and Validation of the QDB Assay. (A) Quantitative analysis of EGFR protein using QDB. (B) Calibration curve spanning 0.01 to 9 μg. (C) Linear dynamic range of the QDB assay. Feasibility and Validation of the QDB assay Serial dilutions of the lysate, ranging from 0.01 to 9 μg, were prepared for QDB analysis. The assay revealed the signal approached saturation when the loaded amount exceeded 1 μg (Fig. 2A and B). Simple linear regression analysis revealed that the QDB assay demonstrated linearity within the range of 0–1 μg, yielding a coefficient of determination (R2) of 0.997 (Fig. 2C). Consequently, relative to Western blotting, the QDB assay is better suited for analyzing samples with limited protein input. The analytical performance of the QDB assay was evaluated. Based on the standard curve (Fig. 2C), the assay demonstrated excellent linearity within the 0–1 μg range (R2 = 0.997). Based on SNRs of 3:1 and 10:1, the limits of detection and quantification were determined to be 0.01 and 0.03 μg, respectively. Development of a QDB-based assay for EGFR quantification Proteins were extracted from FFPE specimens using a standard deparaffinization and lysis protocol. Total lysates from 89 CRC specimens were spotted onto QDB plates. Antibody performance was evaluated by comparing sample signals against the buffer-only blank control (0.5 μg/μL BSA). Following validation, standard curves were generated using pooled lysates from serial dilutions of purified EGFR protein (Fig. 3A) and high-expression samples (Fig. 3B). Absolute EGFR protein quantification in CRC tissues was determined based on the total protein load measured using QDB.Fig. 3Development of a QDB-Based Assay for EGFR Quantification. (A) Calibration curve and quantification results using purified EGFR protein. (B) Calibration curve and quantification results using high-expression FFPE-derived lysates. Development of a QDB-Based Assay for EGFR Quantification. (A) Calibration curve and quantification results using purified EGFR protein. (B) Calibration curve and quantification results using high-expression FFPE-derived lysates. Absolute quantification of EGFR protein in CRC tissues Samples from Yuhuangding Hospital (n = 89; 42 non-treated, 47 CTX-treated) were quantified through QDB using the standard curve (Fig. 3). EGFR protein levels (n = 89) ranged from 0.05 to 3.85 nmol/g (Fig. 4A). Correlation analysis between samples exhibiting the highest (3.85 nmol/g) and lowest (0.05 nmol/g) EGFR levels and their corresponding Immunohistochemistry (IHC) scores revealed a positive association (Fig. 4B).Fig. 4Absolute Quantification of EGFR Protein in CRC Tissues. (A) Distribution of EGFR protein levels in FFPE tissues (n = 89). (B) Representative IHC images of EGFR expression. Absolute Quantification of EGFR Protein in CRC Tissues. (A) Distribution of EGFR protein levels in FFPE tissues (n = 89). (B) Representative IHC images of EGFR expression. When analyzing the entire cohort, an optimal cutoff value of 0.23 nmol/g was determined through ROC analysis (Fig. S1), allowing for stratification into high- and low-EGFR expression groups. The optimal EGFR cutoff value of 0.23 nmol/g was determined by ROC analysis using survival outcome in the full combined cohort. This unified threshold was applied consistently for all subsequent subgroup stratifications (non-CTX-treated and CTX-treated subgroups). Twelve patients were randomly selected from the CTX group. Intra-assay precision was assessed via triplicate measurements for each sample, yielding a coefficient of variation (CV) that ranged from 0.39% to 3.68%. Inter-assay variability was evaluated across three independent experimental runs, with inter-assay CVs ranging from 0.45% to 10.95%. These results confirm the high precision and reliability of the QDB assay. Patients' clinicopathological features Table 1 summarizes the clinicopathological characteristics of all FFPE specimens. The Retrospectively collected 89 CRC specimens (42 non-treated and 47 CTX-treated cases) were obtained from Yantai Yuhuangding Hospital.Table 1Clinicopathological characteristics of colorectal cancer.Table 1Clinical characteristicsCetuximabPNo medication (n = 42)Medication (n = 47)Age, median (range)57.7 (21–79)58.7 (33–89)0.607Sex, n (%)0.445 Male30 (71)30 (64) Female12 (29)17 (36)TNM Stage, n (%)T0.999 1-23 (7.1)2 (4.2) 3-439 (92.9)31 (66) Unknown0 (0)14 (29.8)N0.161 05 (11.9)8 (17) 1-337 (88.1)25 (53.2)Unknown0 (0)14 (29.8)M0.040 02 (4.8)9 (19.1) 140 (95.2)38 (80.9) Unknown0 (0)0 (0)Tumor location, n (%) liver0 (0)5 (10.6)0.038 colon6 (14.3)5 (10.6) sigmoid colon8 (19)9 (19.1) right half of the colon7 (16.7)1 (2.1) rectum21 (50)27 (57.4)Recurrence, n (%)0.266 Yes9 (21.4)13 (27.7) No33 (78.6)34 (72.3)Death event, n (%)0.083 Yes21 (50)32 (68.1) No21 (50)15 (31.9)Expression of EGFR, median (range)0.75(0.12–3.85)0.25 (0.05–0.72)0.039Note. The chi-square analyses for T and N stage either exclude unknowns. Table 1Clinicopathological characteristics of colorectal cancer.Table 1Clinical characteristicsCetuximabPNo medication (n = 42)Medication (n = 47)Age, median (range)57.7 (21–79)58.7 (33–89)0.607Sex, n (%)0.445 Male30 (71)30 (64) Female12 (29)17 (36)TNM Stage, n (%)T0.999 1-23 (7.1)2 (4.2) 3-439 (92.9)31 (66) Unknown0 (0)14 (29.8)N0.161 05 (11.9)8 (17) 1-337 (88.1)25 (53.2)Unknown0 (0)14 (29.8)M0.040 02 (4.8)9 (19.1) 140 (95.2)38 (80.9) Unknown0 (0)0 (0)Tumor location, n (%) liver0 (0)5 (10.6)0.038 colon6 (14.3)5 (10.6) sigmoid colon8 (19)9 (19.1) right half of the colon7 (16.7)1 (2.1) rectum21 (50)27 (57.4)Recurrence, n (%)0.266 Yes9 (21.4)13 (27.7) No33 (78.6)34 (72.3)Death event, n (%)0.083 Yes21 (50)32 (68.1) No21 (50)15 (31.9)Expression of EGFR, median (range)0.75(0.12–3.85)0.25 (0.05–0.72)0.039Note. The chi-square analyses for T and N stage either exclude unknowns. Clinicopathological characteristics of colorectal cancer. Note. The chi-square analyses for T and N stage either exclude unknowns. χ2 analysis revealed that CTX treatment was significantly associated with M stage (χ2 = 4.238, df = 1, P = 0.040), tumor location (χ2 = 10.151, df = 1, P = 0.038); CTX treatment was not associated with sex (χ2 = 0.583, df = 1, P = 0.445), T stage (χ2 = 0.035, df = 1, P = 0.999), N stage (χ2 = 1.963, df = 1, P = 0.161), recurrence (χ2 = 1.238, df = 1, P = 0.266), or mortality (χ2 = 3.012, df = 1, P = 0.083). However, post-hoc power analysis indicated that our study had 52% power to detect a medium effect size (Cohen's d = 0.43) at α = 0.05, suggesting that this non-significant trend may be attributable to limited statistical power. Age comparison using an independent samples t-test revealed no significant difference between non-CTX group (n = 42, mean ± SD: 57.57 ± 12.015 years) and CTX-treated group (n = 47, mean ± SD: 58.85 ± 11.352 years) (t = −0.516, df = 87, P = 0.607). Association between EGFR expression and survival Growing evidence indicates that elevated EGFR expression is associated with adverse clinical outcomes [24]. Survival analysis by log-rank test revealed a statistically significant association between EGFR expression levels and survival outcomes (P = 0.035), indicating that higher EGFR expression correlates with reduced OS in patients with CRC (Fig. 5).Fig. 5Association between EGFR Expression and Overall Survival in the Full Cohort. Kaplan-Meier survival curves stratified by EGFR protein levels (determined through QDB). Association between EGFR Expression and Overall Survival in the Full Cohort. Kaplan-Meier survival curves stratified by EGFR protein levels (determined through QDB). To assess the association between EGFR expression levels (high versus low) and patient mortality, the χ2 test was used. It demonstrated a significant association between EGFR expression and elevated mortality (χ2 = 4.534, df = 1, P = 0.033) (Table 2). All expected cell frequencies exceeded 5, fulfilling the test assumptions.Table 2Correlation analysis between EGFR expression levels and survival rates in 89 cases.Table 2DeceasedNot Deceasedχ2 = 4.534P = 0.033Low expression11 (12.4%)15 (16.9%)26 (29.2%)High expression42 (47.2%)21 (23.6%)63 (70.8%)53 (59.6%)36 (40.4%)89 (100%)Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. Table 2Correlation analysis between EGFR expression levels and survival rates in 89 cases.Table 2DeceasedNot Deceasedχ2 = 4.534P = 0.033Low expression11 (12.4%)15 (16.9%)26 (29.2%)High expression42 (47.2%)21 (23.6%)63 (70.8%)53 (59.6%)36 (40.4%)89 (100%)Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. Correlation analysis between EGFR expression levels and survival rates in 89 cases. Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. To assess the association between EGFR expression levels (high versus low) and survival outcomes in non-CTX and CTX treatment groups, respectively, subgroup analyses were performed. Kaplan-Meier analysis revealed no significant association between EGFR expression and survival in the non-CTX group (P = 0.149; Fig. 6A) nor in the CTX group (P = 0.109; Fig. 6B). Post-hoc power analysis indicated that, if α = 0.05 and a medium effect size (Cohen's d = 0.3), 88 samples would be required to achieve 80% power to reject the null hypothesis. However, with only 42 samples in the non-CTX group and 47 in the CTX group, this study was underpowered to detect a significant association between EGFR expression and survival in these subgroup analyses. Consequently, the observed non-significant trends (P = 0.149 and 0.109) warrant cautious interpretation, and larger confirmatory studies are warranted.Fig. 6Association between EGFR Expression and Overall Survival by Treatment Subgroup. (A) Kaplan-Meier OS curves stratified by EGFR expression in the non-CTX group (P = 0.149). (B) Kaplan-Meier OS curves stratified by EGFR expression in the CTX-treated group (P = 0.109). Association between EGFR Expression and Overall Survival by Treatment Subgroup. (A) Kaplan-Meier OS curves stratified by EGFR expression in the non-CTX group (P = 0.149). (B) Kaplan-Meier OS curves stratified by EGFR expression in the CTX-treated group (P = 0.109). Trend toward improved survival with CTX in high EGFR subgroup In the CTX treatment group, patients with high versus low EGFR expression had significantly improved survival (P = 0.038). Among patients with high EGFR expression (n = 26), the survival rate was 19.2% (5/26), while among those with low expression (n = 21), the survival rate was 47.6% (10/21). χ2 analysis revealed significant association between EGFR expression and mortality in CTX-treated patients (χ2 = 4.309, df = 1, P = 0.038). All expected cell frequencies exceeded 5, meeting the test assumptions (Table 3). Owing to the limited sample size, a true treatment effect could not be confirmed. Additional investigations with larger cohorts are warranted to validate these findings.Table 3Correlation analysis between EGFR expression levels and survival rates in 47 cases.Table 3DeceasedNot Deceasedχ2 = 4.309P = 0.038Low expression11 (52.4%)10 (47.6%)21 (100%)High expression21 (80.8%)5 (19.2%)26 (100%)321547Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. Table 3Correlation analysis between EGFR expression levels and survival rates in 47 cases.Table 3DeceasedNot Deceasedχ2 = 4.309P = 0.038Low expression11 (52.4%)10 (47.6%)21 (100%)High expression21 (80.8%)5 (19.2%)26 (100%)321547Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. Correlation analysis between EGFR expression levels and survival rates in 47 cases. Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. Analysis revealed that elevated EGFR expression is associated with a poorer prognosis. Furthermore, CTX therapy was associated with prolonged survival in the high-expression subgroup (Table 4). In the untreated group, 100% (21/21) of total deaths occurred in patients with high EGFR expression. In the CTX-treated group, however, the proportion of total deaths accounted for by high-EGFR-expression patients decreased to 65.6% (21/32). By contrast, low-expression patients accounted for 0% (0/21) of total deaths in the untreated group versus 34.4% (11/32) in the treated group. Elevated EGFR expression correlates with a poorer overall prognosis, potentially due to CTX resistance.Table 4Correlation analysis between CTX treatment status and survival rates.Table 4Treatment StatusTotal Deaths (n)Number of Deaths with High Expression (n)Proportion of Total Deaths in High-Expression Subgroup (%)Non-CTX-treated2121100CTX-treated322165.6Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. Table 4Correlation analysis between CTX treatment status and survival rates.Table 4Treatment StatusTotal Deaths (n)Number of Deaths with High Expression (n)Proportion of Total Deaths in High-Expression Subgroup (%)Non-CTX-treated2121100CTX-treated322165.6Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. Correlation analysis between CTX treatment status and survival rates. Note. Patient stratification was performed based on the biomarker cutoff of 0.23 nmol/g, defining low- and high-biomarker subgroups. Currently, no consensus exists regarding the criteria for CTX use. We assume that this decision is based on clinicopathological factors, specifically RAS/BRAF status and tumor location, rather than EGFR expression levels alone. Discussion Although IHC remains the gold standard for assessing protein biomarkers in solid tumors, its limited objectivity and reproducibility have been well documented. Developing alternative approaches for consistent quantification is crucial for clinical use despite continuous attempts to standardize IHC [28,29]. This study developed a robust QDB-based assay, which enables the absolute and precise quantification of EGFR in CRC tissues in clinical practice. Compared with the semi-quantitative scoring applied in conventional IHC (for example, 0, 1+, 2+, 3+), QDB offers continuous absolute quantification, thereby minimizing subjective bias and enabling precise and reproducible measurements. By employing a validated anti-EGFR antibody that specifically binds to the extracellular domain of EGFR, cross-reactivity with HER2/HER3 was minimized, ensuring the detected signal exclusively reflects EGFR abundance. Standardized membrane drying and controlled ECL substrate incubation prevented signal overdevelopment, preserving linearity across the 0–1 μg total protein range (R2 = 0.997). EGFR signals were normalized to correct for variations in lysis efficiency and pipetting errors, yielding a CV < 5% across triplicate measurements and ensuring reliable inter-sample comparability. The 96-well plate format enabled the analysis of 96 samples within 4 h, highlighting high-throughput profiling of large-scale clinical cohorts. This precise quantification capability is expected to address the limitations of IHC, which merely distinguishes ‘positive’ from ‘negative’, and facilitate nuanced grading of EGFR expression. Additional research should establish EGFR thresholds using large-scale cohorts to improve identification of subgroups likely to derive benefit from anti-EGFR therapies (for example, CTX). This would enable precision medicine, optimizing treatment decisions by avoiding ineffective therapies in low-expression patients and thereby reducing unnecessary toxicity and healthcare costs. In the past decade, QDB technology has been extensively validated and implemented for the detection of clinically relevant tumor markers, attributable to its high reliability and robust quantitative performance. For instance, in breast cancer studies, QDB has been effectively applied to quantify the expression levels of HER2 and the cell proliferation marker Ki67 [30]. Preclinical and clinical studies have demonstrated that HER2 protein levels quantified by QDB exhibit strong concordance with reference standards from IHC and fluorescence in situ hybridization. By generating semi-quantitative data with greater speed and objectivity, this approach facilitates molecular subtyping and prognostic evaluation of breast cancer. The QDB has also been applied in gastric cancer research. A recent study leveraged QDB to quantify HER2 expression for guiding targeted therapy. It also extended its application to the quantitative assessment of EGFR [31]. The findings revealed that QDB accurately discriminates between distinct EGFR expression levels in gastric cancer tissues. Its quantitative outputs correlate significantly with patients’ clinical and pathological features. It serves as an efficient screening tool for identifying candidates for EGFR-targeted therapy. Collectively, these preclinical and clinical applications establish QDB as a reliable and high-throughput protein quantification platform capable of rapidly and accurately detecting key tumor driver proteins and proliferation markers, with quantitative outputs demonstrating strong clinical efficacy. Accumulating evidence suggests that acquired drug resistance pathogenesis involves intrinsic molecular aberrations within tumor cells, including genetic alterations (for example, mutations in RAS [32] and RAF [33]), dysregulation of EGFR or its ligands [34], aberrant activation of EGFR downstream signaling molecules [35], and modulation by extrinsic factors outside the EGFR pathway. These intrinsic alterations directly affect drug targets or bypass signal-blocking mechanisms, whereas extrinsic mechanisms originate from tumor microenvironment dysregulation [36], including impaired immune cell function, which reduces synergistic cytotoxicity [37], aberrant cancer-associated fibroblast infiltration, which remodels the tumor extracellular matrix barrier [38], and dysregulated angiogenesis, which worsens impairments in tumor nutrient supply and drug delivery. All of these modifications contribute to acquired resistance in patients. To evaluate patient responsiveness to EGFR-targeted therapy, a multimodal efficacy monitoring framework has been developed. This framework integrates Raman spectroscopy and metabolomics to characterize chemotherapy-induced metabolic alterations [39], proteomics and phosphoproteomics to profile differential protein expression and phosphorylation events [40], transcriptomic analysis and co-expression subtyping to delineate gene expression signatures [41], and DNA mutation profiling to identify putative resistance-associated genetic alterations [42], collectively generating actionable insights for clinical patient stratification. Our approach focuses on quantifying EGFR expression levels and offers a critical complementary strategy for elucidating resistance mechanisms. This study revealed that QDB-derived absolute EGFR quantification has demonstrated significant clinical relevance. It suggested that elevated EGFR levels correlated significantly with specific clinicopathological characteristics (tumor location, M stage, and nodal metastasis), thereby positioning it as a potential marker for tumor aggressiveness. Consequently, precise EGFR quantification may enable prognostic stratification and guide the selection of targeted therapies. In addition, this study proposes a putative threshold of 0.23 nmol/g for prognostic assessment in RAS/BRAF wild-type CRC. However, these findings warrant cautious interpretation. This study has several limitations to be considered during result interpretation. The cohort size was limited, comprising 89 RAS/BRAF wild-type CRC cases (42 untreated; 47 CTX-treated), which compromised statistical power, hindered adequate control for confounding factors, and reduced the generalizability of the results. Future investigations with larger cohorts, prospective designs, and multicenter data integration are required to validate these findings. Integrating molecular biology experiments (for example, in vitro cell models and in vivo animal studies) will help elucidate the underlying mechanisms of these observations, thereby offering robust evidence to inform RAS/BRAF wild-type CRC management. Notably, this analysis has an important limitation: there was a high rate of missing T- and N-stage data among patients treated with CTX, with unknown staging information in 14 of 47 patients (29.8%). These patients were excluded from the chi-square analysis of tumor staging. According to available clinical records, missing staging information was mostly caused by incomplete pre-treatment staging workups, indicating potential systematic missingness. Exclusion of these cases may introduce bias into the statistical comparisons of T and N stage, which should be taken into account when interpreting our findings. In summary, the QDB-based immunoassay enables absolute and precise quantification of EGFR protein in CRC specimens. This method provides a robust tool for establishing EGFR as a predictive biomarker. It is expected to inform patient selection for anti-EGFR targeted therapy (for example, CTX). Furthermore, precise EGFR quantification may serve as an objective metric for prognosis. It facilitates a transition from binary (positive/negative) assessment to a stratified, expression-driven treatment paradigm by establishing quantitative thresholds. This would optimize patient selection, improve therapeutic efficacy, and reduce unnecessary toxicity. CRediT authorship contribution statement Ze Li: Writing – original draft, Visualization. Na Li: Investigation, Conceptualization. Quanyong Li: Software. Wenlei Xu: Methodology. Guohua Yu: Writing – review & editing. Wenguo Jiang: Writing – review & editing. Ethics declaration Written informed consent to take part in the study and to publish the article has been obtained from all participants or their legal representatives. The privacy rights of participants have been observed. This study was performed in compliance with relevant laws, regulatory frameworks and guidelines where the research took place. This study was approved by the Ethics Committee of Binzhou Medical University. (Approval No. No. DYPD2023-290) This research follows the CARE guidelines and the CARE checklist. Consent for publication All authors have read and approved the final manuscript for publication. Funding This study was supported by the 10.13039/501100007129Natural Science Foundation of Shandong Province (Grant ZR2023MH218) and the 10.13039/100014103Key Technology Research and Development Program of Shandong Province (Grant No.2023CXPTO12). Declaration of competing interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Jiang Wenguo reports financial support was provided by the Natural Science Foundation of Shandong Province. Jiang Wenguo reports financial support was provided by Key Technology Research and Development Program of Shandong Province. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.